Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group
Open Access
- 25 March 2022
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 46, 101362
Abstract
No abstract availableKeywords
Funding Information
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Roche
- Ministerio de Sanidad, Consumo y Bienestar Social
- Gilead Sciences
This publication has 15 references indexed in Scilit:
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19New England Journal of Medicine, 2021
- Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trialThe Lancet Respiratory Medicine, 2021
- Tocilizumab in Patients Hospitalized with Covid-19 PneumoniaNew England Journal of Medicine, 2021
- Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19JAMA Internal Medicine, 2021
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe PneumoniaJAMA Internal Medicine, 2021
- A minimal common outcome measure set for COVID-19 clinical researchThe Lancet Infectious Diseases, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Clinical and immunological features of severe and moderate coronavirus disease 2019Journal of Clinical Investigation, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020